<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218165</url>
  </required_header>
  <id_info>
    <org_study_id>EA1/062/10</org_study_id>
    <nct_id>NCT01218165</nct_id>
  </id_info>
  <brief_title>Low Grade Inflammation, Gut Microbiota and Barrier Function in Elderly Humans</brief_title>
  <official_title>The Inflammaging Network: Bridging Low Grade Inflammation With Gut Microbiota and Intestinal Barrier Function in Elderly Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular diseases (CVD) are the main cause of death in the European Union. A large part
      of the aging process, including immunosenescence, is explained by an imbalance between
      inflammatory and anti-inflammatory networks, wich results in the low grade chronic
      pro-inflammatory status termed inflammaging. It can contribute to a number of age-related
      chronic diseases (e.g. atherosclerosis, type 2 diabetes, Alzheimer disease, osteoporosis).
      Prevention or delay in onset of chronic diseases can potentially benefit a large segment of
      the elderly population. Now it is hypothesised that a probiotic drink can reduce low-grade
      inflammation through improvement of the gut barrier function and gut microbiota composition
      in elderly people with low-grade inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular diseases (CVD) are the main cause of death in the European Union. A large part
      of the aging process, including immunosenescence, is explained by an imbalance between
      inflammatory and anti-inflammatory networks, wich results in the low grade chronic
      pro-inflammatory status termed inflammaging. It can contribute to a number of age-related
      chronic diseases (e.g. atherosclerosis, type 2 diabetes, Alzheimer disease, osteoporosis).
      Prevention or delay in onset of chronic diseases can potentially benefit a large segment of
      the elderly population. Now it is hypothesised that a probiotic drink can reduce low-grade
      inflammation through improvement of the gut barrier function and gut microbiota composition
      in elderly people with low-grade inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre/post-intervention change in hsCRP</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change (reduction) of hsCRP over a 6-week period in older persons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>6 weeks</time_frame>
    <description>Intestinal permeability tests will be performed with a triple sugar test (5 g LAC, 10 g MAN, and 20 g SAC dissolved in 100 ml of water).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool: Stool: Real-Time-PCR</measure>
    <time_frame>6 weeks</time_frame>
    <description>During screening and post intervention quantitative Real-Time-PCR of bacterial 16S ribosomal RNA from feces will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood screening</measure>
    <time_frame>6 weeks</time_frame>
    <description>Day 0 - Screening: hsCRP, leukocytes, erythrocytes, haemoglobin, haematokrit, sodium, potassium, glucose, total cholesterol, HDL, LDL, bilirubin total, bilirubin direct, ASAT, ALAT, creatinine Day 42 - post intervention: hsCRP, leukocytes, erythrocytes, haemoglobin, haematokrit, glucose, total cholesterol, HDL, LDL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Handgrip strength will be evaluated using the Jamar vigorimeter (Preston, Jackson, MI 49204, USA) on Day 0 in the screening period and at the end of the intervention trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance status</measure>
    <time_frame>6 weeks</time_frame>
    <description>The short physical performance battery (SPPB) (24) will be performed at the start and at the end of the intervention trial. SPPB is used to assess lower extremity function. It evaluates balance, gait, strength, and endurance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Aged</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>without intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group receives a probiotic drink daily for 6 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic drink</intervention_name>
    <description>This group receives a probiotic drink daily for 6 week.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>without intervention</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men &gt;65 years of age.

          -  Body mass index: 22-34,9 kg/m²

          -  non-smokers

        Intervention trial:

          -  hsCRP &gt; 1 mg/L (Screening blood test)

          -  normal blood count (Screening blood test)

          -  normal ALAT, ASAT and serum creatinine levels (Screening blood test)

        Exclusion Criteria:

          -  any major non-organic disease, including malign diseases (haematological,
             inflammatory, metabolic,)

          -  any major organ disease, including neoplastic diseases.

          -  intake of antibiotics within the last 6 weeks

          -  chronic therapy with analgetics (incl. acetylsalicylic acid)

          -  chronic therapy with proton pump inhibitors

          -  regular intake of probiotic bacteria products within the last 3 weeks

          -  chronic anti-inflammatory therapy with NSARs or previous therapy within the last 20
             days

          -  subjects with expected non-compliance to protocol guidelines

          -  subjects that participate in other trials
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luzia Valentini, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herbert Lochs, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Innsbruck</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jörg-Dieter Schulzke, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Bereswill, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Swidsinski, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007 Jan;128(1):92-105. Epub 2006 Nov 20. Review.</citation>
    <PMID>17116321</PMID>
  </reference>
  <reference>
    <citation>Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl. 2005 May;6(2):21-9. Review.</citation>
    <PMID>15823493</PMID>
  </reference>
  <reference>
    <citation>Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.</citation>
    <PMID>12551878</PMID>
  </reference>
  <reference>
    <citation>Imhof A, Fröhlich M, Loewel H, Helbecque N, Woodward M, Amouyel P, Lowe GD, Koenig W. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem. 2003 Apr;49(4):669-72.</citation>
    <PMID>12651827</PMID>
  </reference>
  <reference>
    <citation>Lannergård A, Friman G, Ewald U, Lind L, Larsson A. Serum amyloid A (SAA) protein and high-sensitivity C-reactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults. Acta Paediatr. 2005 Sep;94(9):1198-202.</citation>
    <PMID>16279005</PMID>
  </reference>
  <reference>
    <citation>Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010 Feb;74(2):213-20. Epub 2010 Jan 9. Review.</citation>
    <PMID>20065609</PMID>
  </reference>
  <reference>
    <citation>Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18;286(3):327-34.</citation>
    <PMID>11466099</PMID>
  </reference>
  <reference>
    <citation>Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr. 2006 Feb;83(2):470S-474S. Review.</citation>
    <PMID>16470015</PMID>
  </reference>
  <reference>
    <citation>Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology. 1995 Jul;136(7):3054-61.</citation>
    <PMID>7789332</PMID>
  </reference>
  <reference>
    <citation>Pirlich M, Norman K, Lochs H, Bauditz J. Role of intestinal function in cachexia. Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):603-6. Review.</citation>
    <PMID>16912557</PMID>
  </reference>
  <reference>
    <citation>D'Souza T, Sherman-Baust CA, Poosala S, Mullin JM, Morin PJ. Age-related changes of claudin expression in mouse liver, kidney, and pancreas. J Gerontol A Biol Sci Med Sci. 2009 Nov;64(11):1146-53. doi: 10.1093/gerona/glp118. Epub 2009 Aug 19.</citation>
    <PMID>19692671</PMID>
  </reference>
  <reference>
    <citation>Saltzman JR, Kowdley KV, Perrone G, Russell RM. Changes in small-intestine permeability with aging. J Am Geriatr Soc. 1995 Feb;43(2):160-4.</citation>
    <PMID>7836641</PMID>
  </reference>
  <reference>
    <citation>Beaumont DM, Cobden I, Sheldon WL, Laker MF, James OF. Passive and active carbohydrate absorption by the ageing gut. Age Ageing. 1987 Sep;16(5):294-300.</citation>
    <PMID>3120502</PMID>
  </reference>
  <reference>
    <citation>Guarner F. Enteric flora in health and disease. Digestion. 2006;73 Suppl 1:5-12. Epub 2006 Feb 8. Review.</citation>
    <PMID>16498248</PMID>
  </reference>
  <reference>
    <citation>Ordovas JM, Mooser V. Metagenomics: the role of the microbiome in cardiovascular diseases. Curr Opin Lipidol. 2006 Apr;17(2):157-61. Review.</citation>
    <PMID>16531752</PMID>
  </reference>
  <reference>
    <citation>Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009 Nov 11;1(6):6ra14. doi: 10.1126/scitranslmed.3000322.</citation>
    <PMID>20368178</PMID>
  </reference>
  <reference>
    <citation>Degens H. Age-related skeletal muscle dysfunction: causes and mechanisms. J Musculoskelet Neuronal Interact. 2007 Jul-Sep;7(3):246-52. Review.</citation>
    <PMID>17947808</PMID>
  </reference>
  <reference>
    <citation>Hamer M, Molloy GJ. Association of C-reactive protein and muscle strength in the English Longitudinal Study of Ageing. Age (Dordr). 2009 Sep;31(3):171-7. doi: 10.1007/s11357-009-9097-0. Epub 2009 May 23.</citation>
    <PMID>19466582</PMID>
  </reference>
  <reference>
    <citation>Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006 Jun;119(6):526.e9-17.</citation>
    <PMID>16750969</PMID>
  </reference>
  <reference>
    <citation>Goebel A, Buhner S, Schedel R, Lochs H, Sprotte G. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Rheumatology (Oxford). 2008 Aug;47(8):1223-7. doi: 10.1093/rheumatology/ken140. Epub 2008 Jun 7.</citation>
    <PMID>18540025</PMID>
  </reference>
  <reference>
    <citation>Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008 Aug;135(2):568-79. doi: 10.1053/j.gastro.2008.04.017. Epub 2008 Apr 18.</citation>
    <PMID>18570896</PMID>
  </reference>
  <reference>
    <citation>Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005 Jul;43(7):3380-9.</citation>
    <PMID>16000463</PMID>
  </reference>
  <reference>
    <citation>Swidsinski A. Standards for bacterial identification by fluorescence In situ hybridization within eukaryotic tissue using ribosomal rRNA-based probes. Inflamm Bowel Dis. 2006 Aug;12(8):824-6; author reply 826-7.</citation>
    <PMID>16917237</PMID>
  </reference>
  <reference>
    <citation>Puthoff ML, Janz KF, Nielson D. The relationship between lower extremity strength and power to everday walking behaviors in older adults with functional limitations. J Geriatr Phys Ther. 2008;31(1):24-31.</citation>
    <PMID>18489805</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Luzia Valentini</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Healthy Eldery People</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

